These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36945773)

  • 21. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
    Roddie C; Lekakis LJ; Marzolini MAV; Ramakrishnan A; Zhang Y; Hu Y; Peddareddigari VGR; Khokhar N; Chen R; Basilico S; Raymond M; Vargas FA; Duffy K; Brugger W; O'Reilly MA; Wood L; Linch DC; Peggs KS; Bachier C; Budde EL; Lee Batlevi C; Bartlett N; Irvine D; Tholouli E; Osborne W; Ardeshna KM; Pule MA
    Blood; 2023 May; 141(20):2470-2482. PubMed ID: 36821767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
    Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
    J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
    Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
    Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
    Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
    Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
    Ba D; Li H; Liu R; Zhang P; Tang Y
    Apoptosis; 2023 Dec; 28(11-12):1534-1545. PubMed ID: 37243774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
    Spiegel JY; Patel S; Muffly L; Hossain NM; Oak J; Baird JH; Frank MJ; Shiraz P; Sahaf B; Craig J; Iglesias M; Younes S; Natkunam Y; Ozawa MG; Yang E; Tamaresis J; Chinnasamy H; Ehlinger Z; Reynolds W; Lynn R; Rotiroti MC; Gkitsas N; Arai S; Johnston L; Lowsky R; Majzner RG; Meyer E; Negrin RS; Rezvani AR; Sidana S; Shizuru J; Weng WK; Mullins C; Jacob A; Kirsch I; Bazzano M; Zhou J; Mackay S; Bornheimer SJ; Schultz L; Ramakrishna S; Davis KL; Kong KA; Shah NN; Qin H; Fry T; Feldman S; Mackall CL; Miklos DB
    Nat Med; 2021 Aug; 27(8):1419-1431. PubMed ID: 34312556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.
    Zhang T; Wang T; You F; Li Z; Chen D; Zhang K; Tian S; Sheng B; Wu H; Jiang L; Ma R; An G; Meng H; Yang L
    Transpl Immunol; 2022 Apr; 71():101538. PubMed ID: 35051588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
    Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
    Qin H; Ramakrishna S; Nguyen S; Fountaine TJ; Ponduri A; Stetler-Stevenson M; Yuan CM; Haso W; Shern JF; Shah NN; Fry TJ
    Mol Ther Oncolytics; 2018 Dec; 11():127-137. PubMed ID: 30581986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Brillembourg H; Martínez-Cibrián N; Bachiller M; Alserawan L; Ortiz-Maldonado V; Guedan S; Delgado J
    Br J Haematol; 2024 May; 204(5):1649-1659. PubMed ID: 38362778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH
    J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
    Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
    Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
    Front Immunol; 2022; 13():873789. PubMed ID: 35572515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
    Jia H; Wang Z; Wang Y; Liu Y; Dai H; Tong C; Guo Y; Guo B; Ti D; Han X; Yang Q; Wu Z; Han W
    J Hematol Oncol; 2019 Jun; 12(1):57. PubMed ID: 31182121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
    Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
    J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma.
    Huang L; Li J; Yang J; Zhang X; Zhang M; He J; Zhang G; Li W; Wang H; Li J; Lu P
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
    Zhang Y; Li S; Wang Y; Lu Y; Xu Y; Rao Q; Wang H; Xing H; Tian Z; Tang K; Lv L; Wang M; Wang J
    Exp Hematol Oncol; 2022 Mar; 11(1):15. PubMed ID: 35317863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.